PEAK PHARMACEUTICALS, INC.: 10-Q filed 2015-08-13
What PEAK PHARMACEUTICALS, INC. reported in its quarterly report filed 2015-08-13 (fiscal Q3 2015): 22 published measures, 48 facts as tagged in accession 0001137050-15-000111.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-08-13
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001137050-15-000111 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PEAK PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 406,157 | USD | |
| At 2014-09-30 | 490,908 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 330,133 | USD | |
| At 2014-09-30 | 54,427 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 76,024 | USD | |
| At 2014-09-30 | 436,481 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | -488,483 | USD | 91 |
| 2014-10-01 to 2015-06-30 | -1,893,779 | USD | 273 |
| 2014-04-01 to 2014-06-30 | -1,630,090 | USD | 91 |
| 2013-10-01 to 2014-06-30 | -2,492,464 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2015-06-30 | -209,632 | USD | 273 |
| 2013-10-01 to 2014-06-30 | -721,971 | USD | 273 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 178,812 | USD | 91 |
| 2014-10-01 to 2015-06-30 | 440,842 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-06-30 | 1,315,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2015-06-30 | -2,187 | USD | 273 |
| 2013-10-01 to 2014-06-30 | -35,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | -5,752,834 | USD | |
| At 2014-09-30 | -3,859,055 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 372,895 | USD | |
| At 2014-09-30 | 458,269 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2015-06-30 | -495 | USD | 273 |
| 2014-04-01 to 2014-06-30 | -666,240 | USD | 91 |
| 2013-10-01 to 2014-06-30 | -696,628 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 330,133 | USD | |
| At 2014-09-30 | 54,427 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 1,701 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 667,295 | USD | 91 |
| 2014-10-01 to 2015-06-30 | 2,334,126 | USD | 273 |
| 2014-04-01 to 2014-06-30 | 963,850 | USD | 91 |
| 2013-10-01 to 2014-06-30 | 1,820,486 | USD | 273 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 95,550 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 138,432 | USD | 91 |
| 2014-10-01 to 2015-06-30 | 310,471 | USD | 273 |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 317,244 | USD | 91 |
| 2014-10-01 to 2015-06-30 | 751,313 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 276 | USD | 91 |
| 2014-10-01 to 2015-06-30 | 12,143 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 78,363,562 | shares | |
| At 2014-09-30 | 78,163,562 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 5,821,022 | USD | |
| At 2014-09-30 | 4,287,720 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 633,852 | USD | 91 |
| 2014-10-01 to 2015-06-30 | 2,334,728 | USD | 273 |
| 2014-04-01 to 2014-06-30 | 961,765 | USD | 91 |
| 2013-10-01 to 2014-06-30 | 1,406,287 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 13,773 | USD | 91 |
| 2013-10-01 to 2014-09-30 | 4,861 | USD | 365 |
Inspect the source
- Entity
- PEAK PHARMACEUTICALS, INC. / CIK 0001452804
- Captured
- 2026-09-20T09:05:40.595Z
- SEC response SHA-256
3fd5eb06bfdebffa42021b094c4c379c1efd3c7143204265bf035090db070211
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001452804.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))